The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy.
TSH-secreting pituitary tumours are rare but difficult to treat due to a combination of refractory hyperthyroidism and low surgical cure rates. We describe the case of a 21-year-old woman who, despite twin pregnancy, became euthyroid and had dramatic tumour shrinkage on octreotide treatment. To our knowledge, this is the first description of the use of octreotide for a TSH-secreting pituitary adenoma throughout pregnancy.
Blackhurst
G
G
Endocrinology Unit, Molecular Medicine Centre, University of Edinburgh, UK. gblackhurst@ed.ac.uk
Strachan
M W
MW
Collie
D
D
Gregor
A
A
Statham
P F X
PF
Seckl
J E R
JE
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D013972:Thyrotropin / Q000378:metabolism*; D014427:Twins
D018931:Antineoplastic Agents, Hormonal; D013972:Thyrotropin; D015282:Octreotide